Literature DB >> 22505455

The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.

Salvador Iborra1, Helena M Izquierdo, María Martínez-López, Noelia Blanco-Menéndez, Caetano Reis e Sousa, David Sancho.   

Abstract

In order to prime T cells, DCs integrate signals emanating directly from pathogens and from their noxious action on the host. DNGR-1 (CLEC9A) is a DC-restricted receptor that detects dead cells. Therefore, we investigated the possibility that DNGR-1 affects immunity to cytopathic viruses. DNGR-1 was essential for cross-presentation of dying vaccinia virus-infected (VACV-infected) cells to CD8(+) T cells in vitro. Following injection of VACV or VACV-infected cells into mice, DNGR-1 detected the ligand in dying infected cells and mediated cross-priming of anti-VACV CD8(+) T cells. Loss of DNGR-1 impaired the CD8+ cytotoxic response to VACV, especially against those virus strains that are most dependent on cross-presentation. The decrease in total anti-VACV CTL activity was associated with a profound increase in viral load and delayed resolution of the primary lesion. In addition, lack of DNGR-1 markedly diminished protection from infection induced by vaccination with the modified vaccinia Ankara (MVA) strain. DNGR-1 thus contributes to anti-VACV immunity, following both primary infection and vaccination. The non-redundant ability of DNGR-1 to regulate cross-presentation of viral antigens suggests that this form of regulation of antiviral immunity could be exploited for vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505455      PMCID: PMC3336985          DOI: 10.1172/JCI60660

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

1.  Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing.

Authors:  Zhilong Yang; Daniel P Bruno; Craig A Martens; Stephen F Porcella; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever.

Authors:  S Kettle; A Alcamí; A Khanna; R Ehret; C Jassoy; G L Smith
Journal:  J Gen Virol       Date:  1997-03       Impact factor: 3.891

Review 3.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

Review 4.  Approaching the asymptote? Evolution and revolution in immunology.

Authors:  C A Janeway
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

Review 5.  Tolerance, danger, and the extended family.

Authors:  P Matzinger
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

Authors:  Juliana Idoyaga; Ashira Lubkin; Christopher Fiorese; Mireille H Lahoud; Irina Caminschi; Yaoxing Huang; Anthony Rodriguez; Björn E Clausen; Chae Gyu Park; Christine Trumpfheller; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 7.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product.

Authors:  M Dobbelstein; T Shenk
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 9.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

10.  Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells.

Authors:  Brian T Edelson; Wumesh KC; Richard Juang; Masako Kohyama; Loralyn A Benoit; Paul A Klekotka; Clara Moon; Jörn C Albring; Wataru Ise; Drew G Michael; Deepta Bhattacharya; Thaddeus S Stappenbeck; Michael J Holtzman; Sun-Sang J Sung; Theresa L Murphy; Kai Hildner; Kenneth M Murphy
Journal:  J Exp Med       Date:  2010-03-29       Impact factor: 14.307

View more
  74 in total

1.  Dendritic cells: actin a dangerous part.

Authors:  Yvonne Bordon
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

2.  Immunology: Actin' dangerously.

Authors:  Gordon D Brown
Journal:  Nature       Date:  2012-05-31       Impact factor: 49.962

Review 3.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

Review 4.  Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance.

Authors:  Christopher J Nirschl; Niroshana Anandasabapathy
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 5.  Activation and trafficking of CD8+ T cells during viral skin infection: immunological lessons learned from vaccinia virus.

Authors:  Samuel J Hobbs; Jossef F Osborn; Jeffrey C Nolz
Journal:  Curr Opin Virol       Date:  2017-10-25       Impact factor: 7.090

6.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 7.  Dendritic cells in central nervous system autoimmunity.

Authors:  Christopher Sie; Thomas Korn
Journal:  Semin Immunopathol       Date:  2016-11-25       Impact factor: 9.623

Review 8.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

10.  A new RIDDle in DC-mediated cross-presentation.

Authors:  Manikandan Subramanian; Ira Tabas
Journal:  Nat Immunol       Date:  2014-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.